Catalyst Biosciences

Equities

CBIO

US14888D2080

Market Closed - Nasdaq Other stock markets 10:30:00 03/07/2024 pm IST			5-day change	1st Jan Change
11.72 ^USD	-2.98%		+25.21%	+52.81%

2023	Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index	CI
2023	Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.	CI

CATALYST BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)

January 30, 2020 at 02:33 am IST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 23, 2020, the Compensation Committee of the Board of Directors of Catalyst Biosciences, Inc. (the "Company"), approved the following cash bonuses for fiscal year 2019 for the Company's executive officers, based on the Company's achievement of certain product development and business objectives in fiscal year 2019.





                                                        2019 Cash
                Name and Position                         Bonus
                Nassim Usman, Ph.D.
                President & Chief Executive Officer     $  211,560
                Howard Levy, M.B.B.Ch., Ph.D., M.M.M.
                Chief Medical Officer                   $  110,000

--------------------------------------------------------------------------------

Latest news about Catalyst Biosciences

Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index	30/23/30	CI
Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.	30/23/30	CI
Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.	30/23/30	CI
Catalyst Biosciences, Inc. announced that it expects to receive $4.999815 million in funding from GNI USA, Inc.	27/23/27	CI
Catalyst Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/23/27	CI
Catalyst Biosciences, Inc. has Changed its Name to Gyre Therapeutics, Inc	29/23/29	CI
North American Morning Briefing : China Trouble Hits Sentiment	18/23/18	DJ
Catalyst Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Catalyst Biosciences Files Registration Statement on Behalf of Selling Stockholders	25/23/25	MT
Catalyst Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
North American Morning Briefing : Hopes Build for -3-	15/23/15	DJ
Catalyst Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
North American Morning Briefing : Stocks Seen -2-	30/23/30	DJ
Catalyst Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	30/23/30	CI
GC Biopharma Takes Over Catalyst Biosciences' Orphan Hematology Disorder Treatment Candidates	01/23/01	MT
Wider-Than-Expected Trade in Goods Deficit Kicks Off Tuesday's Data Dump, Stifling US Equity Futures	28/23/28	MT
Top Premarket Gainers	28/23/28	MT
Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer	20/23/20	CI
Top Premarket Decliners	13/23/13	MT
GNI to Take Controlling Stake in Nasdaq-listed Catalyst Biosciences via Liver Fibrosis Drug Development Deals; Shares Up 3%	28/22/28	MT
Sector Update: Health Care Edging Higher at Tuesday Close	28/22/28	MT
Sector Update: Health Care Stocks Still Struggling for Direction	28/22/28	MT
Sector Update: Health Care	28/22/28	MT
Catalyst Biosciences Acquires F351, Controlling Interest in Continent From GNI Group	27/22/27	MT
Transcript : Catalyst Biosciences, Inc., GNI Group Ltd. - Special Call	27/22/27

Chart Catalyst Biosciences

Duration

Period

More charts

Company Profile

Catalyst Biosciences, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of Hydronidone for the treatment of nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease in the United States. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the United States and generated pharmacokinetic (PK), safety and tolerability data of single and multiple ascending doses of Hydronidone in United States healthy subjects. Hydronidone is a structural analogue of the approved anti-fibrotic (pulmonary fibrosis) drug pirfenidone. Hydronidone has been shown to inhibit both p38y kinase activity and TGF-b1- induced excessive collagen synthesis in vitro in hepatic stellate cells (HSCs), which are recognized as critical events in the development and progression of fibrosis in the liver.

Sector

More about the company

Income Statement Evolution

More financial data